BioSpace News Archive

In simple words, apoptosis assays refers to programmed cell deaths, which are able to regulate genetically cell ablation over the period of normal development.

Aridis Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors with extensive backgrounds in life sciences and biotechnology investing to purchase in a registered direct offering 1,134,470 shares of common stock for $7.4925 per share.

ReGelTec, Inc., a medical device company developing a percutaneous treatment for chronic low back pain, announced that eleven patients with degenerative disc disease have been enrolled in the Company’s Early Feasibility Study in Barranquilla, Colombia.

Medtronic plc, the global leader in medical technology, will outline the company’s strategy for driving accelerated revenue growth and sustainable double-digit total shareholder returns at its virtual 2020 Investor Day.

“Molecular Glue” Protein Degradation Serves as Alternative Approach for Difficult-to-Treat Diseases

New CleanPlex® ACE2 & TMPRSS2 Panel Assesses Differences in Patients’ Genetic Susceptibility to COVID-19 Infection and to Developing Severe Disease

CytoSorbents Corporation and Aferetica srl, two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica’s PerLife™ ex vivo organ perfusion system and CytoSorbents’ ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion.

Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

Taysha Gene Therapies Inc. announced that it has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-102, an AAV9-based gene therapy in development for the treatment of Rett syndrome.

Orca Bio, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Orca-T (NCT04013685). Orca-T is an investigational allogeneic, high-precision cell therapy for patients with blood cancers who are eligible for a hematopoietic (blood) stem cell transplant. In addition, Orca-T has received ODD from the FDA for enhancing cell engraftment in patients who qualify fo